Mir-892b Silencing Activates Nf-Kappa B And Promotes Aggressiveness In Breast Cancer
Lili Jiang,Liang Yu,Xin Zhang,Fangyong Lei,Lan Wang,Xiangxia Liu,Shu Wu,Jinrong Zhu,Geyan Wu,Lixue Cao,Aibin Liu,Libing Song,Jun Li
DOI: https://doi.org/10.1158/0008-5472.CAN-15-1770
IF: 11.2
2016-01-01
Cancer Research
Abstract:The strength and duration of NF-kappa B signaling is tightly controlled at multiple levels under physiologic conditions, but the mechanism underlying constitutive activation of the NF-kappa B pathway in cancer remains unclear. In this study, we investigated miRNA-mediated regulation of the NF-kappa B cascade in breast cancer. We report that miR-892b expression was significantly downregulated in human breast cancer specimens and correlated with poor patient survival. Overexpression of miR-892b in breast cancer cells significantly decreased tumor growth, metastatic capacity, and the ability to induce angiogenesis, whereas miR-892b depletion enhanced these properties, in vitro and in vivo. Furthermore, we demonstrate that miR-892b attenuated NF-kappa B signaling by directly targeting and suppressing multiple mediators of NF-kappa B, including TRAF2, TAK1, and TAB3, and thus, miR-892b silencing in breast cancer cells sustains NF-kappa B activity. Moreover, miR-892b downregulation was attributed to aberrant hypermethylation of its promoter. Taken together, our results provide insight into a new mechanism by which NF-kappa B signaling becomes constitutively activated in breast cancer and suggest a tumor-suppressive role for miR-829b, prompting further investigation into miRNA mimics for cancer therapy. (C)2016 AACR.